Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02993120 · ClinicalTrials.gov registry record
Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States
A clinical trial, sponsored by Amgen.
- Completed
- Registry status
- 5,006
- Enrollment target
NCT02993120 is a clinical trial that has completed, run by Amgen. The registered enrollment target is 5,006 participants.
The verdict
NCT02993120 has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- 5,006 participants
- Enrollment target
Study Summary
This is a multicenter observational cohort study with both retrospective and prospective data collection components in subjects with ASCVD. The purpose of this study is to better understand cholesterol treatment patterns in the context of a changing landscape in subjects with ASCVD.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,006 participants |
| Start Date | 2016-12-06 |
| Est. Completion | 2021-08-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02993120
The ClinicalTrials.gov registry entry for NCT02993120 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5,006 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02993120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02993120 about?
NCT02993120 is a clinical study titled "Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States". This is a multicenter observational cohort study with both retrospective and prospective data collection components in subjects with ASCVD. The purpose of this study is to better understand cholesterol treatment patterns in the context of a changing landscape in subjects with ASCVD.
What is the current status of trial NCT02993120?
This trial is currently completed. The enrollment target is 5,006 participants. The study started on 2016-12-06. Estimated completion is 2021-08-06.
Who is sponsoring clinical trial NCT02993120?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.